Abstract
We have undertaken some basic and clinical studies on midecamycin granules with following results:
1) After ingestion of 4g of midecamycin granules, peak blood levels (1.51μg/ml on an average) appeared at one hour in infants, detectable amount lasting for 6 hours.
2) Urinary excretion within 6 hours ranged from 1.1 to 2.7% of the drug dosed.
3) In the treatment of a total of 19 acute cases, consisting of 9 cases of tonsillitis, 7 cases of lacunar tonsillitis and 3 cases of bronchitis, midecamycin was found effective in 79% of the cases.
4) In all the 3 cases of pneumonia due to Mycoplasma, response to midecamycin was assessed as excellent.
5) Hepatic and renal functions tests performed in cases treated with the drug for a prolonged period (40-50 mg/kg for 13-18 days) revealed no undesirable effect, indicating that midecamycin can be administered continuously to younger infants with infections.
